媒体报导

Oral insulin to be a game changer: Oramed CEO tells CNBC Squawk Box Asia Nadav Kidron, CEO of Oramed Pharmaceuticals, talks about the company's latest offering  

Josh Hexter, Oramed’s COO, spoke with BioTuesdays.com about the conclusion of the Phase IIb study, and about what's next for Oramed: Oramed hopes to start Phase 3 oral insulin trial next year

Injectable insulin has been around since 1923, but oral insulin has proven elusive to date. Oramed Pharmaceuticals' successful Phase IIB trial for oral insulin has shown that it can be done. http://seekingalpha.com/article/3987206-oramed-now-first-show-evidence-insulin-can-taken-orally  

Creating a safe, effective, tolerable oral insulin has become the holy grail of diabetes drug development, and Israel-based Oramed is one of the frontrunners in this race... http://www.biopharmadive.com/news/orameds-oral-insulin-shines-in-mid-stage-trials/419657/  

https://marketexclusive.com/weekly-biotech-report-part-ii-oramed-pharmaceuticals-inc-nasdaqormp/2016/05/

http://www.reuters.com/article/us-oramed-insulin-idUSKCN0Y91F2

Josh Hexter, Oramed's COO, spoke with Be Forum and about the company's recent China deal. www.beforum.org/the-bulletin/dancing-with-dragons

Josh Hexter, Oramed's COO, spoke with BioTuesdays.com about Oramed's progress and future advances. "Our ORMD-0801 drug candidate has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and [...]

seekingalpha.com/article/3723676-50-million-plus-royalties-deal-indicates-bright-future-for-orameds-oral-insulin?app=1&auth_param=k8111%3A1b5r8j9%3A005181aa590ef2f22df1979bdbb995c2&uprof=78